Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TAKE Solutions Limited (TAKE.NS)
Chennai, IN
TAKE Solutions Limited, operating across the United States, Asia Pacific, and Europe, specializes in providing expert services and cutting-edge solutions for the life sciences and supply chain management sectors. For the life sciences industry, the company delivers technology-driven and proprietary solutions, alongside consulting and practical services covering clinical trials, regulatory compliance, and patient safety. Its specific offerings in this area include clinical research, development of generic drugs, data analytics, regulatory affairs management, and pharmacovigilance. Beyond this, TAKE Solutions also offers IT infrastructure and support, comprehensive supply chain management, engineering, design, and sourcing services. The company caters to a diverse client base, encompassing both major and smaller innovative biopharmaceutical and medical device firms, as well as generic drug producers. Established in 2000, its main office is located in Chennai, India. TAKE Solutions Limited functions as a subsidiary of TAKE Solutions Pte. Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.52% | +10.90% | -31.78% | -26.74% | +0.03% | -22.56% | +234.74% | +77.76% | -56.56% | -81.35% | -66.01% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-71.1% Q1'26: +187.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-23.9% Q1'26: -5.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-3.6% Q1'26: -1.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-6.0% ★ Q1'26: -10.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.3% ★ Q1'26: +2.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2011 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.00B
est: 5.02B (-0.3%)
|
7.30B
est: 7.24B (+0.9%)
|
10.30B
est: 9.90B (+4.1%)
|
13.45B
est: 13.68B (-1.7%)
|
15.87B
est: 15.63B (+1.6%)
|
20.39B
est: 19.99B (+2.0%)
|
22.13B
est: 25.37B (-12.8%)
|
7.74B
est: 8.92B (-13.2%)
|
6.53B
est: 12.52B (-47.9%)
|
1.89B
est: 15.22B (-87.6%)
|
656.08M
est: 54.36B (-98.8%)
|
| EBITDA |
1.09B
est: -440.83M (+348.1%)
|
1.08B
est: -636.50M (+270.3%)
|
2.25B
est: 1.83B (+22.8%)
|
2.75B
est: 2.92B (-5.9%)
|
3.13B
est: 2.82B (+10.7%)
|
3.87B
est: 3.62B (+6.9%)
|
1.86B
est: 4.55B (-59.0%)
|
-2.86B
est: -783.56M (-265.2%)
|
269.00M
est: -1.10B (+124.4%)
|
-209.79M
est: 1.97B (-110.6%)
|
-1.05B
est: -4.80B (+78.1%)
|
| EBIT |
877.89M
est: -795.98M (+210.3%)
|
918.27M
est: -1.15B (+179.9%)
|
1.51B
est: 1.67B (-9.8%)
|
1.78B
est: 2.21B (-19.5%)
|
2.01B
est: 2.01B (-0.1%)
|
2.33B
est: 2.63B (-11.3%)
|
192.85M
est: 2.92B (-93.4%)
|
-4.02B
est: -1.41B (-183.8%)
|
-487.25M
est: -1.99B (+75.5%)
|
-378.19M
est: 35.20M (-1,174.4%)
|
-1.13B
est: -8.67B (+87.0%)
|
| Net Income |
735.51M
est: 851.78M (-13.7%)
|
698.83M
est: 794.62M (-12.1%)
|
1.20B
est: 1.39B (-13.7%)
|
1.43B
est: 1.67B (-14.4%)
|
1.60B
est: 1.63B (-1.8%)
|
1.77B
est: 2.06B (-13.8%)
|
-123.60M
est: 2.25B (-105.5%)
|
-4.52B
est: -1.89B (-139.6%)
|
-7.82B
est: 701.99M (-1,214.3%)
|
-1.00B
est: -218.85M (-358.2%)
|
-1.20B
est: 6.56B (-118.2%)
|
| SGA |
698.44M
est: 1.28B (-45.5%)
|
1.06B
est: 1.85B (-42.7%)
|
881.38M
est: 1.73B (-49.0%)
|
1.36B
est: 7.27B (-81.3%)
|
1.69B
est: 7.76B (-78.3%)
|
2.13B
est: 10.45B (-79.6%)
|
2.94B
est: 13.49B (-78.2%)
|
757.04M
est: 2.28B (-66.8%)
|
793.35M
est: 3.20B (-75.2%)
|
102.86M
est: 3.89B (-97.4%)
|
2.36M
est: 13.96B (-100.0%)
|
| EPS |
5.83
est: 5.82 (+0.1%)
|
5.82
est: 5.43 (+7.1%)
|
9.97
est: 10.05 (-0.8%)
|
11.22
est: 10.15 (+10.5%)
|
12.19
est: 11.89 (+2.6%)
|
12.13
est: 15.15 (-19.9%)
|
-0.85
est: 14.00 (-106.1%)
|
-30.91
est: -12.90 (-139.6%)
|
-53.50
est: 4.80 (-1,214.6%)
|
-6.86
est: 10.80 (-163.5%)
|
-8.18
est: 44.65 (-118.3%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vandana Gupta | Company Secretary & Compliance Officer | 4M | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TAKE.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
